Barclays
TYRA icon

Barclays’s Tyra Biosciences TYRA Stock Holding History

Barclays’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$648K Sell
20,275
-813,124
-98% -$26.9M ﹤0.01% 3065
2026
Q1 		$31.9M Buy
833,399
+757,090
+992% +$24.5M 0.01% 903
2025
Q4 		$2.01M Buy
76,309
+19,183
+34% +$352K ﹤0.01% 2931
2025
Q3 		$799K Sell
57,126
-4,429
-7% -$50.5K ﹤0.01% 3508
2025
Q2 		$589K Buy
61,555
+19,044
+45% +$181K ﹤0.01% 3666
2025
Q1 		$395K Sell
42,511
-559
-1% -$7.23K ﹤0.01% 3669
2024
Q4 		$599K Buy
43,070
+5,445
+14% +$98.8K ﹤0.01% 3713
2024
Q3 		$885K Buy
37,625
+25,106
+201% +$527K ﹤0.01% 3436
2024
Q2 		$200K Buy
12,519
+2,669
+27% +$45.9K ﹤0.01% 3580
2024
Q1 		$162K Sell
9,850
-9,377
-49% -$154K ﹤0.01% 4227
2023
Q4 		$266K Buy
19,227
+16,721
+667% +$216K ﹤0.01% 4285
2023
Q3 		$34.5K Sell
2,506
-282
-10% -$4.18K ﹤0.01% 4014
2023
Q2 		$47.5K Sell
2,788
-3,997
-59% -$58K ﹤0.01% 3857
2023
Q1 		$109K Buy
6,785
+3,204
+89% +$38.1K ﹤0.01% 4125
2022
Q4 		$27.2K Buy
3,581
+3,025
+544% +$21.4K ﹤0.01% 4747
2022
Q3 		$5K Sell
556
-102
-16% -$933 ﹤0.01% 4510
2022
Q2 		$5K Sell
658
-1,257
-66% -$10K ﹤0.01% 4791
2022
Q1 		$20K Buy
+1,915
New +$22.7K ﹤0.01% 4450

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Barclays's TYRA Position: Q2 2026 in Review

Barclays reduced its Tyra Biosciences (TYRA) stake by 98% in Q2 2026, selling an estimated $26.9M and leaving 20,275 shares worth $648K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Barclays first reported a position in TYRA in Q1 2022 and has held it in 18 quarters since. The position peaked at $31.9M in Q1 2026. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Barclays held 20,275 shares of Tyra Biosciences worth $648K as of Q2 2026.
  • Barclays sold 813,124 Tyra Biosciences shares in Q2 2026, an estimated $26.9M.
  • Tyra Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3065 holding.
  • Barclays first reported a position in Tyra Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Tyra Biosciences position peaked at $31.9M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.